# Artificial Intelligence In Genomics Market

> Artificial Intelligence in Genomics Market Research Report By Application (Drug Discovery, Genetic Testing, Personalized Medicine, Agrigenomics, Clinical Diagnostics), By Technology (Machine Learning, Deep Learning, Natural Language Processing, Reinforcement Learning, Computer Vision), By End User (Pharmaceutical Companies, Research Institutes, Healthcare Providers, Biotechnology Companies), By Deployment Mode (On-Premises, Cloud-Based, Hybrid) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 38.4%
- **2025:** USD 1.16 Billion
- **2035:** USD 30.05 Billion
- **Key Players:** Illumina, Inc., NVIDIA Corporation, Microsoft Corporation, Alphabet (Google DeepMind), Thermo Fisher Scientific, Tempus AI, Inc., SOPHiA GENETICS SA, QIAGEN N.V.

**Report ID:** MRFR/HC/20633-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/artificial-intelligence-in-genomics-market-22233

---

## Market Summary

## Artificial Intelligence In Genomics Market Summary

The Artificial Intelligence In Genomics Market reached USD 1.16 Billion in 2025 and enters the forecast window at USD 1.61 Billion in 2026, climbing to USD 30.05 Billion by 2035 at a 38.4% CAGR. Two catalysts anchor that trajectory. The U.S. National Institutes of Health now hosts the world's largest linked genomic and clinical dataset — more than 535,000 whole genome sequences tied to nearly 482,000 electronic health records [[1]](https://nih.gov). In June 2025 the UK committed £650 million to offer whole-genome sequencing to every newborn, with national rollout starting in 2026 [[11]](https://doi.org/10.1016/j.eclinm.2025.103387). Neither program is deliverable without machine interpretation.

Sequencing hardware stopped being the constraint several years ago. Interpretation became the bottleneck, and the Artificial Intelligence in Genomics Market is what replaced it. Rule-based variant annotation pipelines and manual curation queues are giving way to sequence-to-function models: Google DeepMind's AlphaGenome, released in June 2025, predicts regulatory effects across DNA stretches up to one million base pairs and has attracted roughly 3,000 researchers across 160 countries within seven months [[4]](https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome)[[6]](https://statnews.com). Illumina and NVIDIA formalised the compute side in January 2025, porting DRAGEN onto GPUs and folding BioNeMo and RAPIDS into Illumina Connected Analytics [[7]](https://illumina.com)[[8]](https://investor.nvidia.com).

North America holds 41.8% of the Artificial Intelligence In Genomics Market, carried by NIH funding depth and a dense pharma buyer base. Asia-Pacific grows fastest at a 44.6% CAGR, propelled by India's Genome India Project and Chinese sequencing capacity [[13]](https://indiabioscience.org). Europe sits second at 25.6%, where the Artificial Intelligence In Genomics Market runs on public health-system procurement rather than venture capital. The decade ahead belongs to whoever can validate models across ancestries the current training data barely covers.

## Key Report Takeaways

### • By Technology

- Machine learning holds 58.8% of the Artificial Intelligence In Genomics Market in 2025, reflecting entrenched variant-classification workflows.
- Natural language processing is the fastest-expanding technology at a 40.2% CAGR through 2035
- Deep learning architectures generate USD 0.28 Billion in 2025 revenue

### • By Application

- Drug discovery and development commands 32.0% revenue share, the largest single application of the Artificial Intelligence In Genomics Market
- Precision medicine posts a 40.6% CAGR, the fastest application-level growth on record.

### • By Region

- North America contributes USD 0.49 Billion in 2025
- Asia-Pacific advances at a 44.6% CAGR, outpacing every other region in the Artificial Intelligence In Genomics Market
- Europe holds a 25.6% share, concentrated in Germany and the UK

## Market Size and Forecast (2021–2035)

Estimates below triangulate vendor-reported analytics revenue, disclosed public genomics program budgets, sequencing instrument install-base data, and bottom-up modelling of interpretation spend per genome. Historical values for the Artificial Intelligence In Genomics Market reflect audited filings where available and modelled revenue where private companies dominate a segment.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Sequencing cost collapse per genome | +7.2 pp | Global | Medium-term (2–4 yr) |   |
| National population genomics programs | +6.4 pp | NA, Europe, APAC | Long-term (≥4 yr) | [1][11] |
| Genomic foundation models in production | +5.8 pp | Global | Medium-term (2–4 yr) | [4][6] |
| Pharma platform deals for target discovery | +5.1 pp | NA, Europe | Short-term (≤2 yr) | [7][8] |
| GPU-accelerated secondary analysis | +4.3 pp | Global | Short-term (≤2 yr) | [7] |
| Regulatory clarity on AI evidence | +3.6 pp | NA, Europe | Medium-term (2–4 yr) | [3][19] |
| Precision oncology reimbursement expansion | +3.0 pp | NA, Europe, Japan | Long-term (≥4 yr) | [10] |

### National Population Genomics Programs

Public budgets, not private ones, set the floor here. The UK's £650 million newborn sequencing commitment covers roughly a decade of rollout beginning 2026, following a Genomics England pilot that identified rare treatable conditions in approximately one in 200 babies [[11]](https://doi.org/10.1016/j.eclinm.2025.103387). India moved in parallel: Prime Minister Modi released Genome India Project data in January 2025 covering 10,000 genomes across 83 population groups, assembled by more than 20 institutions [[13]](https://indiabioscience.org)[[14]](https://genomeindia.in). Each program creates a procurement line for interpretation software that did not exist three years earlier.

### Genomic Foundation Models Reaching Production

AlphaGenome marked the shift from task-specific classifiers to general sequence-to-function prediction. The model handles gene expression, chromatin accessibility, histone modification, transcription factor binding and splice junction prediction from a single architecture [[4]](https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome). DeepMind released source code and weights for non-commercial use in January 2026 after publication in Nature [[6]](https://statnews.com). Open weights compress the build-versus-buy calculus for mid-tier vendors, who can now fine-tune rather than pretrain.

### Pharma Platform Deals and Accelerated Compute

Compute partnerships converted [AI genomics](https://www.marketresearchfuture.com/reports/ai-genomics-market-31278) from research overhead into an infrastructure purchase. NVIDIA announced four life-sciences partnerships at the January 2025 J.P. Morgan Healthcare Conference, with Illumina, IQVIA, Mayo Clinic and the Arc Institute [[8]](https://investor.nvidia.com). The Illumina agreement targets multi-omic analysis and sovereign AI genomics deployments — nations wanting world-class interpretation without exporting population data [[7]](https://illumina.com)[[22]](https://genengnews.com). That sovereignty framing is reshaping tender language across the Gulf and Southeast Asia.

### Regulatory Clarity on Model Evidence

FDA issued its first cross-centre draft guidance on AI in drug and biological product development on 6 January 2025, proposing a risk-based credibility assessment framework tied to a defined context of use [[3]](https://fda.gov)[[25]](https://dlapiper.com). CDER had reviewed more than 500 submissions containing an AI component between 2016 and 2023 before drafting it [[23]](https://casrai.org/guides/fda-ai-guidance). EMA and the Heads of Medicines Agencies published a coordinated AI workplan running through 2028 [[19]](https://ema.europa.eu). Sponsors now know what evidence to collect, which shortens sales cycles for validated platforms.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Ancestry bias in training data | −4.8 pp | Global | Long-term (≥4 yr) | [13][15] |
| Fragmented data-privacy and sovereignty rules | −4.1 pp | Europe, APAC, MEA | Medium-term (2–4 yr) | [18] |
| Clinical validation and reimbursement lag | −3.4 pp | Global | Medium-term (2–4 yr) | [3] |
| Shortage of clinical bioinformaticians | −2.9 pp | Global | Long-term (≥4 yr) | [15] |
| Compute and storage cost inflation | −2.2 pp | APAC, SA, MEA | Short-term (≤2 yr) | [8] |

### Ancestry Bias in Training Data

Models inherit the demographics of the cohorts that trained them. A widely cited 2022 analysis found participants of European ancestry accounted for 86.3% of genome-wide association study data [[13]](https://indiabioscience.org). Correction is underway but incomplete: All of Us reports 86% of its 747,000-plus participants come from historically underrepresented communities, and 77% of its earlier 245,388-genome release met the same criterion [[1]](https://nih.gov)[[2]](https://nature.com/articles/s41586-023-06957-x). Genomics England's Diverse Data initiative carries £22.0 million to sequence up to 25,000 participants of non-European ancestry [[15]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12081226). Until validation datasets match deployment populations, health systems outside North America and Western Europe discount vendor accuracy claims — and price accordingly.

### Data Sovereignty and Fragmented Privacy Regimes

Genomic data is the hardest category to move across borders. The EU Artificial Intelligence Act, Regulation (EU) 2024/1689, layers obligations onto systems already governed by GDPR's special-category provisions [[18]](https://eur-lex.europa.eu). Buyers respond by demanding in-country deployment, which fragments what would otherwise be a single cloud product into per-jurisdiction instances. That fragmentation is precisely what the sovereign AI genomics positioning taken by Illumina and NVIDIA is designed to monetise [[22]](https://genengnews.com), but it raises delivery costs for smaller vendors without regional infrastructure.

### Validation and Reimbursement Lag

Clinical adoption trails technical capability by years. FDA's credibility framework requires evidence proportional to model risk, and higher-risk applications demand lifecycle maintenance rather than one-time validation [[3]](https://fda.gov)[[21]](https://onlinelibrary.wiley.com). Payers, separately, reimburse tests rather than interpretation layers. Vendors consequently bundle analytics into assay pricing, which suppresses visible software revenue and understates real penetration.

## Opportunities

## Artificial Intelligence In Genomics Market Opportunities

### Sovereign Genomics Infrastructure in Emerging Markets

Gulf governments, Southeast Asian ministries and African health systems desire genomic capacity at a national level without exporting demographic data overseas. This is addressed directly by deployment packages that combine on-premise GPU clusters with pretrained interpretation models [[22]](https://genengnews.com). Middle East & Africa demand is driven by Saudi Arabia and the UAE who combined constitute a little over half of demand and procurement is skewed toward turnkey national platforms over per-seat software licenses.

### Data Monetisation Through Federated Real-World Evidence

The clinical genomic data is being aggregated as a product in its own right. SOPHiA GENETICS reached the two million analyzed patient profiles milestone in March 2025, from 800 institutions in 72 countries — a real-world evidentiary asset that it now sells to biopharma in addition to the diagnostic platform [[9]](https://sophiagenetics.com). In federated architectures, institutions can contribute signal without giving away records, avoiding sovereignty limits in.

### Newborn and Population Screening at National Scale

England’s 10-year newborn sequencing deployment produces ongoing annual interpretation volume rather than one-off project revenue [[11]](https://doi.org/10.1016/j.eclinm.2025.103387). Similar schemes are under development in Australia, Qatar and the Nordics [[15]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12081226). The screening tasks value throughput and false-positive suppression over model originality, which benefits incumbents with regulatory track records.

### Multi-Omic Integration Beyond DNA

All of Us entered the multi-omic era in 2026 with proteomics on approximately 10,000 individuals, RNA sequencing on nearly 9,000, and long-read genomes on over 14,500 [[1]](https://nih.gov). The Artificial Intelligence In Genomics Market scales the workload as the interpretive complexity increases with each additional modality.

### Agricultural and Livestock Genomics

Crop and livestock breeding programs apply the same variant-effect prediction machinery to non-human genomes at a fraction of the regulatory burden. Adoption is fastest in Brazil and Argentina, where breeding cycles are commercially compressed.

## Future Outlook

## Artificial Intelligence In Genomics Market Future Outlook

### Foundation Models Absorb the Interpretation Layer

Task-specific tools will not survive the decade as standalone products. AlphaGenome already predicts gene expression, splicing, chromatin accessibility and transcription factor binding from one model [[4]](https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome), and open weights since January 2026 mean the capability floor is now public [[6]](https://statnews.com). Differentiation shifts to proprietary clinical data, validation evidence and workflow integration — not model architecture.

### Sovereign Compute Becomes a Procurement Category

Nations that would not export population data will buy the stack instead. The Artificial Intelligence In Genomics Market is already restructuring around this, with sovereign AI genomics named explicitly in the Illumina–NVIDIA collaboration [[22]](https://genengnews.com). Expect national tenders to bundle sequencers, GPUs and interpretation licences into single awards through 2030.

### Multi-Omic Convergence Raises the Compute Floor

DNA alone is becoming insufficient. All of Us added proteomics, RNA sequencing and long-read genomes in 2026, with further multi-omic releases planned [[1]](https://nih.gov). Combining modalities compounds analytical difficulty rather than adding to it linearly, which sustains demand growth in the Artificial Intelligence In Genomics Market even if sequencing volumes plateau.

### Evidence Standards Consolidate Around Regulators

FDA's credibility framework and the EMA–HMA workplan through 2028 are converging on comparable expectations: define the context of use, size the validation to the risk, maintain the model over its lifecycle [[3]](https://fda.gov)[[19]](https://ema.europa.eu). That convergence favours scaled vendors able to fund continuous revalidation and squeezes point-solution startups toward acquisition.

## Segment Insights

## Artificial Intelligence In Genomics Market Segmentation

Segmentation of the Artificial Intelligence In Genomics Market follows six dimensions, with component and technology accounting for the sharpest competitive divergence.

### By Component

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Software | 39.2% share | Variant interpretation and reporting platforms |
| Services | 39.9% CAGR (2026–2035) | Validation, curation and managed bioinformatics |
| Hardware | USD 0.31 Billion | GPU clusters and accelerated sequencing compute |

Software leads the Artificial Intelligence In Genomics Market today because interpretation platforms are where clinical liability concentrates. Services grow faster for a less flattering reason: most buyers lack the internal bioinformatics staff to operate the software they license, and vendors are absorbing that gap as managed delivery.

### By Technology

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Machine Learning | 58.8% share | Variant classification and quality control |
| Deep Learning | USD 0.28 Billion | Sequence-to-function and structural prediction |
| Natural Language Processing | 40.2% CAGR (2026–2035) | Literature curation and clinical note extraction |
| Other Technologies | 5.5% share | Graph methods and federated learning |

Classical machine learning retains majority share because accredited laboratories cannot casually swap validated classifiers. Natural language processing grows fastest as curation moves from manual literature review to automated evidence extraction — the single largest labour cost in clinical variant reporting.

### By Functionality

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Genome Sequencing | 41.1% share | Secondary and tertiary analysis throughput |
| Gene Editing | USD 0.26 Billion | Guide design and off-target prediction |
| Gene Prediction | 15.4% share | Non-coding regulatory annotation |
| Clinical Workflow Tools | 41.8% CAGR (2026–2035) | Reporting, triage and EHR integration |
| Other Functionality | 8.5% share | Pharmacogenomics and ancestry inference |

Genome sequencing software and bioinformatics solutions are occupying the greatest market share owing to the number of secondary and tertiary data processing that is necessitated by high-throughput genomic runs. Meanwhile, the fastest-expanding functional area is clinical workflow tools, driven by institutional need for automated variation reporting, clinical triage and seamless electronic health record (EHR) integration.

### By Application

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Drug Discovery & Development | 32.0% share | Target identification and patient stratification |
| Precision Medicine | 40.6% CAGR (2026–2035) | Therapy selection in oncology and rare disease |
| Diagnostics | USD 0.23 Billion | Liquid biopsy and hereditary panels |
| Agriculture & Animal Research | 13.1% share | Breeding program optimisation |
| Other Applications | 10.5% share | Forensics and microbial genomics |

Drug discovery dominates the Artificial Intelligence In Genomics Market on budget size alone — pharma target-identification programs carry spending authority no health system matches. Precision medicine grows faster because each validated therapy selection creates recurring per-patient interpretation volume rather than one-off project revenue.

### By Deployment Model

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Cloud-Based | 43.0% share | Elastic compute for variable sequencing volume |
| On-Premise | USD 0.40 Billion | Data residency and sovereignty requirements |
| Hybrid | 42.3% CAGR (2026–2035) | Sensitive data local, model training remote |

Cloud-based deployment captures the leading market share within computational genomics and bioinformatics infrastructure, driven by the need for scalable, elastic compute resources to process fluctuating, high-throughput sequencing volumes. Meanwhile, hybrid architecture represents the fastest-growing segment, allowing institutions to keep sensitive patient genomic data secure locally while leveraging remote cloud infrastructure for heavy model training and secondary analysis.

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Pharmaceutical & Biotechnology | 38.6% share | Target discovery and trial enrichment |
| Academic & Research Institutes | USD 0.28 Billion | Grant-funded cohort analysis |
| Hospitals & Clinics | 41.6% CAGR (2026–2035) | Clinical genomic testing volume |
| Agriculture & Agri-Genomics | 9.1% share | Breeding cycle compression |
| Other End Users | 6.5% share | Government and forensic laboratories |

Pharmaceutical and biotechnology businesses hold the highest market share in computational genomics and bioinformatics, as they rely heavily on in-silico target discovery, biomarker identification, and patient stratification for clinical trials. Alternatively, the hospitals and clinics segment is the fastest-growing end-user group, owing to the high uptake of next-generation sequencing (NGS) panels for routine clinical diagnostics and precision oncology care.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.8% share | NIH cohort scale, pharma target discovery, precision oncology |
| Europe | 25.6% share | Public health-system procurement, newborn screening, AI Act compliance |
| Asia-Pacific | 44.6% CAGR (2026–2035) | National genome programs, sequencing manufacturing, sovereign platforms |
| South America | USD 0.05 Billion | Agri-genomics, oncology diagnostics in private networks |
| Middle East & Africa | 3.9% share | Sovereign genomics infrastructure, consanguinity-driven rare disease |
| Total | USD 1.16 Billion | — |

Regional distribution in the Artificial Intelligence In Genomics Market tracks public research funding more closely than population size or healthcare spend.

### North America

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| US | 82.4% | NIH All of Us scale and pharma platform deals |
| Canada | 10.9% | Genome Canada program funding |
| Mexico | 6.7% | Private oncology diagnostics expansion |

Dominance here rests on a single asset: the NIH All of Us Research Program, now the world's largest integrated genomic and EHR database, having fuelled more than 1,400 peer-reviewed publications from nearly 23,000 researchers [[1]](https://nih.gov). That corpus underwrites nearly every commercial variant-interpretation model trained in the region. Consolidation is active — Tempus AI acquired Ambry Genetics in February 2025, adding a West Coast laboratory and inherited-risk testing capability [[24]](https://finance.yahoo.com). North America remains the reference market where the Artificial Intelligence In Genomics Market sets its pricing benchmarks.

### Europe

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| Germany | 22.8% | Hospital genomics networks, pharma R&D density |
| UK | 21.4% | NHS newborn sequencing and Genomics England |
| France | 14.6% | Plan France Médecine Génomique infrastructure |
| Italy | 8.9% | Regional oncology network digitisation |
| Spain | 7.3% | Rare disease reference centres |
| Nordic Countries | 9.2% | Registry linkage and biobank depth |
| Russia | 4.1% | Domestic sequencing substitution |
| Rest of Europe | 11.7% | EU cross-border research consortia |

Procurement in Europe runs through health ministries, which lengthens cycles but produces multi-year contracts. Britain's £650 million newborn commitment is the largest single genomics line item on the continent [[11]](https://doi.org/10.1016/j.eclinm.2025.103387). Compliance is the differentiator: vendors that can evidence conformity with Regulation (EU) 2024/1689 alongside CE-IVD marking win tenders that pure-play analytics firms cannot enter [[18]](https://eur-lex.europa.eu).

### Asia-Pacific

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| China | 33.6% | Domestic sequencing manufacturing and hospital deployment |
| Japan | 19.2% | Precision oncology reimbursement and aging cohort |
| India | 14.8% | Genome India Project and low-cost service delivery |
| South Korea | 11.3% | National biobank and chaebol pharma R&D |
| ASEAN | 10.4% | Sovereign platform tenders |
| Rest of Asia-Pacific | 10.7% | Australian and New Zealand research programs |

Growth in the Artificial Intelligence In Genomics Market is fastest here because the region is building interpretation capacity and sequencing capacity simultaneously, without legacy pipelines to retire. India's Genome India Project published data on 10,000 genomes across 83 population groups in 2025, targeting an Indian reference genome and low-cost diagnostic arrays [[13]](https://indiabioscience.org)[[14]](https://genomeindia.in). Complete Genomics, sequencing on its DNBSEQ-T1+ platform, partnered with SOPHiA GENETICS in November 2025 to co-market MSK-IMPACT and MSK-ACCESS oncology applications globally [[10]](https://prnewswire.com) — a template for pairing regional hardware with Western analytics.

### South America

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| Brazil | 54.7% | Private hospital oncology and agri-genomics |
| Argentina | 21.3% | Livestock and crop breeding programs |
| Rest of South America | 24.0% | Regional reference laboratory consolidation |

Adoption splits along an unusual line: clinical genomics stays concentrated in private hospital networks serving insured urban populations, while agricultural applications scale faster and with less friction. Brazilian breeding programs apply variant-effect models to soy and cattle genomes at volumes that rival regional clinical throughput.

### Middle East & Africa

| Country | Share of Region | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.4% | Vision 2030 health transformation and national genome program |
| UAE | 22.1% | Emirati Genome Programme and sovereign AI infrastructure |
| South Africa | 18.6% | Infectious disease genomics and academic networks |
| Egypt | 11.2% | National reference laboratory build-out |
| Rest of MEA | 19.7% | Qatari and Israeli research programs |

High consanguinity rates in Gulf populations produce rare-disease burdens that conventional screening handles poorly, creating unusually strong clinical justification for sequencing at population scale. Qatar's national program is explicitly diversifying global reference data by scaling its own generation rather than importing models [[15]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12081226). Buyers here consistently require in-country data residency, which favours vendors offering sovereign deployment.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration sits in the moderate band, with an estimated HHI between 750 and 900 and a top-five combined share of roughly 34–42%. No single vendor controls the full stack from sequencer to clinical report, which keeps partnership economics more important than outright share in the Artificial Intelligence In Genomics Market. Compute providers entered late but hold disproportionate leverage over cost structure.

| Company | Est. Revenue Share Range | Key Offerings for Artificial Intelligence In Genomics Market | Strategic Positioning |
| --- | --- | --- | --- |
| Illumina, Inc. | ~9–12% | DRAGEN, Illumina Connected Analytics | Sequencing incumbent extending into interpretation |
| NVIDIA Corporation | ~7–10% | BioNeMo, Parabricks, RAPIDS, MONAI | Compute layer and foundation model enablement |
| Microsoft Corporation | ~6–9% | Azure Genomics, Nuance clinical AI | Cloud infrastructure and enterprise health accounts |
| Alphabet (Google DeepMind) | ~5–8% | AlphaGenome, AlphaMissense, Google Cloud Life Sciences | Research frontier and open-weight model distribution |
| Thermo Fisher Scientific | ~5–7% | Ion Torrent analytics, Oncomine reporting | Assay-attached analytics with broad lab footprint |
| Tempus AI, Inc. | ~4–6% | Multimodal oncology platform, Ambry inherited-risk testing | Data-asset-led precision oncology |
| SOPHiA GENETICS SA | ~3–5% | SOPHiA DDM, MSK-IMPACT and MSK-ACCESS applications | Cloud-native decentralised clinical analytics |
| QIAGEN N.V. | ~3–5% | QIAGEN Digital Insights, QCI Interpret | Curated knowledge base and variant evidence |
| Roche (Foundation Medicine) | ~2–4% | FoundationOne reporting and analytics | Integrated diagnostics and therapeutics pairing |
| Deep Genomics, Inc. | ~2–3% | BigRNA foundation model, RNA therapeutics discovery | Model-first therapeutic target discovery |
| Freenome Holdings, Inc. | ~1–3% | Multiomics early detection platform | Screening-focused blood-based diagnostics |
| Fabric Genomics, Inc. | ~1–2% | Fabric Enterprise, GEM AI interpretation | Rare disease and newborn screening interpretation |

## Recent News & Developments

## Recent News & Developments

- NIH All of Us Research Program (June 2026): Released data from over 747,000 participants including more than 535,000 whole genome sequences linked to nearly 482,000 electronic health records, plus first-time proteomics, RNA-seq and long-read data — the largest integrated genomic-EHR resource available to model developers [[1]](https://nih.gov).
- Google DeepMind (January 2026): Published AlphaGenome in Nature and released source code and model weights for non-commercial use, seven months after roughly 3,000 researchers across 160 countries began using the API [[6]](https://statnews.com).
- Complete Genomics and SOPHiA GENETICS (November 2025): Announced at AMP in Boston a collaboration to launch MSK-ACCESS and MSK-IMPACT powered by SOPHiA DDM on the DNBSEQ-T1+ platform, broadening global access to precision oncology testing [[10]](https://prnewswire.com).
- UK National Health Service (June 2025): Committed £650 million to offer whole-genome sequencing to every newborn within a decade, with rollout from 2026, following a Genomics England pilot detecting treatable rare conditions in roughly one in 200 babies [[11]](https://doi.org/10.1016/j.eclinm.2025.103387).
- Google DeepMind (June 2025): Launched AlphaGenome, predicting regulatory effects across DNA sequences up to one million base pairs, described by external genomicists as an improvement over prior state-of-the-art sequence-to-function models [[4]](https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome)[[5]](https://nature.com/articles/d41586-025-01998-w).
- SOPHiA GENETICS (March 2025): Announced two million analysed patient genomic profiles at NVIDIA GTC, drawn from 800 institutions across 72 countries, with roughly 45-minute turnaround on uploaded genetic data [[9]](https://sophiagenetics.com).
- Genome India Project (January 2025): Prime Minister Modi released genomic data covering 10,000 individuals from 83 population groups, assembled by more than 20 Indian institutions toward an Indian reference genome [[13]](https://indiabioscience.org)[[14]](https://genomeindia.in).
- Illumina and NVIDIA (January 2025): Announced a collaboration at the J.P. Morgan Healthcare Conference to run DRAGEN on NVIDIA GPUs and integrate BioNeMo, RAPIDS and MONAI into Illumina Connected Analytics, targeting multi-omic analysis and sovereign AI genomics [[7]](https://illumina.com)[[8]](https://investor.nvidia.com)[[22]](https://genengnews.com).
- U.S. Food and Drug Administration (January 2025): Issued the first cross-centre draft guidance on AI supporting regulatory decision-making for drugs and biologics, introducing a risk-based credibility assessment framework [[3]](https://fda.gov)[[25]](https://dlapiper.com).

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Artificial Intelligence In Genomics Market across component, technology, functionality, application, deployment model, end user and geography |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 38.4% (2026–2035) |
| Market Size Checkpoints | USD 1.16 Billion (2025); USD 1.61 Billion (2026); USD 30.05 Billion (2035) |
| Fastest Growing Segments | Services (component); Natural Language Processing (technology); Precision Medicine (application); Hybrid (deployment) |
| Companies Profiled | Illumina, NVIDIA, Microsoft, Alphabet (Google DeepMind), Thermo Fisher Scientific, Tempus AI, SOPHiA GENETICS, QIAGEN, Roche (Foundation Medicine), Deep Genomics, Freenome, Fabric Genomics |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How should a buyer structure contracts to avoid vendor lock-in when entering the Artificial Intelligence In Genomics Market?**
A: Negotiate export rights for annotated variant calls in open formats, not just raw FASTQ. Require that curated interpretation history remains portable at termination. Lock-in here comes from accumulated annotations, not the software [9].

**Q: Is it cheaper to fine-tune an open-weight genomic model than to license a commercial platform?**
A: Fine-tuning is cheaper on compute but not on validation, which dominates total cost in regulated settings. Open weights suit research; clinical deployment still needs documented evidence tied to a defined context of use [3][6].

**Q: What integration work does the Artificial Intelligence In Genomics Market typically underestimate?**
A: LIMS and EHR connectivity, not model accuracy. Most failed deployments stall on sample tracking, result routing and report formatting. Budget roughly a third of first-year cost to integration engineering.

**Q: Who carries liability when an AI-generated variant interpretation proves wrong?**
A: Liability generally rests with the reporting laboratory and signing clinician, not the software vendor, since most licences position outputs as decision support. Review indemnity clauses carefully before assuming otherwise [21].

**Q: How does the Artificial Intelligence In Genomics Market differ for agricultural versus clinical buyers?**
A: Agricultural buyers face no clinical validation burden and prioritise throughput and cost per sample. Sales cycles run months rather than years, and pricing sits well below clinical benchmarks.

**Q: Should procurement teams require ancestry-specific validation evidence?**
A: Yes — request performance metrics stratified by ancestry group for your actual patient population, not aggregate accuracy. Vendors trained predominantly on European-ancestry cohorts often cannot supply this [13][15].

**Q: What signals indicate a genomics AI vendor is acquisition-bound rather than durable?**
A: Watch for single-modality products, absence of regulatory clearances, and revenue concentrated in research rather than clinical accounts. Consolidation has favoured platforms with proprietary clinical data assets [24]. This is an independent market research publication. Estimates and forecasts represent Market Research Future analysis and should be read alongside the cited primary sources.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/artificial-intelligence-in-genomics-market-22233*